1. Home
  2. EAD vs PRTC Comparison

EAD vs PRTC Comparison

Compare EAD & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Income Opportunities Fund

EAD

Allspring Income Opportunities Fund

HOLD

Current Price

$6.65

Market Cap

371.7M

Sector

Finance

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$18.05

Market Cap

400.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EAD
PRTC
Founded
2003
2015
Country
United States
United States
Employees
N/A
90
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
371.7M
400.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EAD
PRTC
Price
$6.65
$18.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
204.1K
3.3K
Earning Date
01-01-0001
04-29-2026
Dividend Yield
8.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$6.24
$14.50
52 Week High
$7.18
$19.92

Technical Indicators

Market Signals
Indicator
EAD
PRTC
Relative Strength Index (RSI) 56.47 69.46
Support Level $6.52 $18.07
Resistance Level $6.91 $19.49
Average True Range (ATR) 0.10 0.49
MACD 0.04 0.39
Stochastic Oscillator 95.45 97.45

Price Performance

Historical Comparison
EAD
PRTC

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: